In contrast, P-VASP assays are clinically established to assess drug responses, e.g. to predict responders and non-responders to antiplatelet drugs to reduce major cardiovascular and cerebral events.151,152 P-VASP responses to sGC activators have been used to detect a higher apo-GC-1/2/Fe(II)GC-1/2 ratio in CAD patients,37 which could be used for mechanism-based therapy in patients with elevated apo-GC-1/2 levels. Here, AOPEP is linked to coronary artery disorder.